Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
January 18, 2002
Slides
Pravastatin-Aspirin
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Introduction Pravastatin-Aspiring, Fred T Fiedorek, MD, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute, Bristol-Myers Squibb ppt htm
Pravastatin-Aspirin Combination, Rene Belder, MD, Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute ppt htm
Efficacy of the Combination: Meta-Analyses, Donald A Berry, PhD, Frank T. McGraw Memorial Chair of Cancer Research, University of Texas, MD Anderson Cancer Center ppt htm
Pravastatin-Aspirin Combination: The Medical Need, Thomas A Pearson, MD, PhD, Albert D Kaiser Professor of Community & Preventive Medicine, University of Rochester, School of Medicine ppt htm